<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068521</url>
  </required_header>
  <id_info>
    <org_study_id>13VR3</org_study_id>
    <nct_id>NCT02068521</nct_id>
  </id_info>
  <brief_title>Versartis Long-Term Safety Study of Somavaratan</brief_title>
  <acronym>VISTA</acronym>
  <official_title>An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versartis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versartis Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol 13VR3 is is a multi-center, open-label study assessing long-term somavaratan
      administration.

      Patients will be monitored for safety throughout their participation in the study. Safety
      will be monitored by physical examination, inspection of injection sites, vital signs,
      clinical laboratory determinations (including fasting glucose, insulin, and lipids), 12-lead
      ECGs (for new treatment naïve subjects and subjects not previously exposed to somavaratan),
      PK/PD assessments, and immunogenicity assessments.

      Adverse events (AEs) and concomitant medications will be captured. AEs will be coded using
      CTCAE v 4.0. AEs will be coded using the MedDRA dictionary and CMs using the WHO Drug
      dictionary.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol 13VR3 is a multi-center, open-label study assessing long-term somavaratan
      administration. It is open to subjects completing a somavaratan study in children with
      growth hormone deficiency (GHD), as well as up to 100 new treatment naïve subjects with GHD.
      All subjects will receive somavaratan 3.5 mg/kg twice monthly. The study will be conducted
      at approximately 70 Pediatric Endocrinology centers in the United States, Canada, and
      Europe.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Safety assessments include recording of adverse events and concomitant medications, monitoring of injection sites, vital signs and clinical laboratory determinations.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Evaluate the changes in pharmacodynamics (PD) responses, bone age, weight, height velocity, height standard deviation scores, metabolic parameters, pubertal development and anti-drug antibody responses during long-term somavaratan treatment</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>PK/PD peak and trough measurements will be assessed throughout the study with assessment of plasma VRS-317 concentrations and IGF-I and its binding proteins measured at pre-specified time points.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pediatric Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Treatment naive subjects with GHD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects who have completed a somavaratan study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somavaratan</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Treatment naive subjects with GHD</arm_group_label>
    <arm_group_label>Subjects who have completed a somavaratan study</arm_group_label>
    <other_name>VRS-317</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Subjects Completing a Previous Somavaratan Study:

          1. Completion of a somavaratan clinical study.

          2. Willing and able to comply with all study procedures.

        Exclusion Criteria for Subjects Completing a Previous somavaratan Study:

          1. Withdrawal from a somavaratan clinical study.

          2. Use of certain medications with potential to alter responses to the test product.

          3. Presence of a significant medical condition.

        Inclusion Criteria for New Treatment Naïve Subjects:

          1. Chronological Age ≥ 3.0 years.

          2. Pre-pubertal status.

          3. Diagnosis of GHD as documented by two or more GH stimulation test results ≤ 10.0
             ng/mL.

          4. Normal thyroid function at Screening Visit in subjects not being treated for
             hypothyroidism.

          5. Normal adrenal function at Screening Visit or within 6 months of the Screening Visit,
             in subjects not being treated for adrenal insufficiency. Subjects with adrenal
             insufficiency must receive glucocorticoid treatment for a minimum of 4 weeks before
             study drug administration.

          6. Pathology relating to cause of GHD must be stable for at least 6 months prior to
             screening.

          7. Legally authorized representatives must be willing and able to give informed consent.

        Exclusion Criteria for New Treatment Naïve Subjects:

          1. Prior/concomitant treatment with any growth promoting agent.

          2. Current, significant disease.

          3. Chromosomal aneuploidy, significant gene mutations or confirmed diagnosis of a named
             syndrome.

          4. Birth weight and/or birth length less than 5th percentile for gestational age.

          5. Prolonged daily use of anti-inflammatory doses of oral glucocorticoids.

          6. Prior history of malignancy.

          7. Treatment with an investigational drug in the 30 days prior to screening.

          8. Known allergy to constituents of the study drug formulation.

          9. Ocular findings suggestive of increased intracranial pressure and/or retinopathy at
             screening.

         10. Significant spinal abnormalities including scoliosis, kyphosis, Chiari malformation,
             and spina bifida variants.

         11. Significant abnormality in screening studies.

         12. History of pancreatitis or undiagnosed chronic abdominal pain.

         13. History of spinal or total body irradiation.

         14. Other pituitary hormone deficiencies that are not properly treated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naureen Sheikh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Versartis Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Humphriss, MBA</last_name>
    <phone>650-963-8587</phone>
    <email>ehumphriss@versartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Charlton, MD</last_name>
    <phone>650-433-2635</phone>
    <email>wcharlton@versartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sierra Medical Research</name>
      <address>
        <city>Clovis</city>
        <state>California</state>
        <zip>93612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital for Children</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Larry C. Deeb, M.D., P.A.</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nancy Wright, M.D., P.A. Pediatric Endocrinology</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2624</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Van Meter Pediatric Endocrinology, P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Barry J. Reiner, M.D., LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheik@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center Children's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versaartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Women and Children's Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14222</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrine Center for Children and Young Adults</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>e Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Humphriss, MBA</last_name>
      <phone>650-963-8587</phone>
      <email>ehumphriss@versartis.com</email>
    </contact>
    <contact_backup>
      <last_name>Naureen Sheikh, PhD</last_name>
      <phone>650-433-2613</phone>
      <email>nsheikh@versartis.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://versartis.com</url>
    <description>Versartis website</description>
  </link>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 26, 2016</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth Hormone Deficiency</keyword>
  <keyword>Pediatric Growth Hormone Deficiency</keyword>
  <keyword>GHD</keyword>
  <keyword>PGHD</keyword>
  <keyword>VRS-317</keyword>
  <keyword>Versartis</keyword>
  <keyword>Growth disorder</keyword>
  <keyword>Long acting growth hormone</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>Weekly growth hormone dosing</keyword>
  <keyword>Semi-monthly growth hormone dosing</keyword>
  <keyword>Monthly growth hormone dosing</keyword>
  <keyword>IGF-I</keyword>
  <keyword>Short stature</keyword>
  <keyword>Height velocity</keyword>
  <keyword>Annual height velocity</keyword>
  <keyword>Growth rate</keyword>
  <keyword>Somavaratan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
